Stock IKT INHIBIKASE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Insiders Inhibikase Therapeutics, Inc.

Equities

IKT

US45719W2052

Delayed Nasdaq
Other stock markets
 10:12:33 2024-05-17 EDT 		5-day change 1st Jan Change
1.8 USD +2.28% Intraday chart for Inhibikase Therapeutics, Inc. +37.41% +41.74%
05-16 Transcript : Inhibikase Therapeutics, Inc., Q1 2024 Earnings Call, May 16, 2024
05-09 Inhibikase Therapeutics Announces Final Pre-Ind Meeting Outcomes for Ikt-001Pro as A Treatment for Pulmonary Arterial Hypertension CI

Insiders

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Inhibikase Therapeutics, Inc. Announces Executive Changes
CI
Inhibikase Therapeutics, Inc. to Appoint C. Warren Olanow as Interim Chief Medical Officer
CI
Inhibikase Therapeutics, Inc Appoints Elizabeth G. O'farrell to its Board of Directors
CI
Inhibikase Therapeutics, Inc. Announces Board Changes
CI
Inhibikase Therapeutics, Inc Announces Board Appointments
CI
Inhibikase Therapeutics, Inc. Elects Anthony Zook to its Board of Directors
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IKT Stock
  4. News Inhibikase Therapeutics, Inc.
  5. Insiders
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW